Strategic partnerships Median Technologies has recently partnered with Olea Medical to deploy eyonis LCS for early lung cancer detection in the US and Europe, signaling a receptive market for AI-powered SaMD integrations with radiology systems and workflow partners.

Enterprise clinical adoption Active participation in major radiology industry events (European Congress of Radiology, RSNA) and FDA-cleared eyonis LCS demonstrations indicate growing clinician and decision-maker interest, presenting opportunities to position end-to-end AI imaging solutions to hospitals and CROs.

AI enabled clinical trials iCRO and eyonis SaMD offerings enhance oncology trial imaging management, suggesting salesOpportunity with biopharmaceutical companies seeking scalable AI-assisted imaging analysis and centralized reading for faster, more accurate trial outcomes.

Expansion potential Global footprint with US and Shanghai subsidiaries, combined with ambitious AI model development for pulmonary nodules and lung cancer screening, points to cross-border sales potential and need for localized regulatory/commercial strategies.

Financial backdrop Revenue scale ($25M-$50M) and substantial funding ($294M) support a credible buying trajectory for larger healthcare organizations and system integrators seeking robust imaging AI platforms, with room for upsell to broader SaMD ecosystems and cloud-based deployments.